Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring
            <i>Acinetobacter baumannii</i>
            and
            <i>Serratia marcescens</i>
            Investigated Using Time-Kill and Disk Approximation Assays

Gaudereto, Juliana Januario; Neto, Lauro Vieira Perdigão; Leite, Gleice Cristina; Martins, Roberta Ruedas; Prado, Gladys Villas Boas do; Rossi, Flávia; Guimarães, Thaís; Levin, Anna S.; Costa, Sílvia Figueiredo

doi:10.1128/aac.02367-18

Cited by 16 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our previous study we evaluated five S marcescens isolates carrying blaKPC-2 and demonstrated that ceftazidime-avibactam was very active and synergistic with meropenem against this pathogen. 13 We could not confirm phenotypical resistance to carbapenem in two isolates. However, there are resistance mechanisms that are inducible and dependent of environment conditions, resulting in different resistance phenotypes.…”

Section: Discussionmentioning

confidence: 81%

Carbapenem‐resistant Serratia marcescens bloodstream infection in hematopoietic stem cell transplantation patients: Will it be the next challenge?

Prado

Mendes

Martins

et al. 2021

Transplant Infectious Dis

Self Cite

View full text Add to dashboard Cite

In the past decade, the incidence of carbapenem-resistant enterobacteria (CRE) infections has risen worldwide, thus increasing the use of polymyxins and aminoglycosides, commonly last resort treatments for these infections. For this reason, questions have been raised about whether the use of these antimicrobials may have some impact on the prevalence of Enterobacteriaceae intrinsically resistant to polymyxins, such as Serratia. 1 Chromosomal carbapenem resistance in Serratia is known since the 1980s; however, Serratia carrying KPC was described only in 2006-2007. 2 Since then, surveillance programs have been reporting decreasing rates of carbapenem-sensitivity in S marcescens, leading to a concern regarding the few remaining therapeutic options to treat these multidrug-resistant (MDR) circulating clones. 3 Although S marcescens is an opportunistic agent of infection, it is not common in hematopoietic stem cell transplantation (HSCT) patients. To our knowledge, there was only one outbreak caused by carbapenem resistant Serratia marcescens (CrSm) in patients with hematological malignancies, which included eight HSCT patients with bloodstream infection, but no reported deaths. 4

show abstract

Section: Discussionmentioning

confidence: 81%

Carbapenem‐resistant Serratia marcescens bloodstream infection in hematopoietic stem cell transplantation patients: Will it be the next challenge?

Prado

Mendes

Martins

et al. 2021

Transplant Infectious Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…A flow chart of the review is depicted in Figure 1 . Eighty-four relevant publications [ 12 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , ...…”

Section: Resultsmentioning

confidence: 99%

Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant Acinetobacter baumannii

et al. 2021

View full text Add to dashboard Cite

Antimicrobial combinations are at the moment the only potential treatment option for pandrug-resistant A. baumannii. A systematic review was conducted in PubMed and Scopus for studies reporting the activity of antimicrobial combinations against A. baumannii resistant to all components of the combination. The clinical relevance of synergistic combinations was assessed based on concentrations achieving synergy and PK/PD models. Eighty-four studies were retrieved including 818 eligible isolates. A variety of combinations (n = 141 double, n = 9 triple) were tested, with a variety of methods. Polymyxin-based combinations were the most studied, either as double or triple combinations with cell-wall acting agents (including sulbactam, carbapenems, glycopeptides), rifamycins and fosfomycin. Non-polymyxin combinations were predominantly based on rifampicin, fosfomycin, sulbactam and avibactam. Several combinations were synergistic at clinically relevant concentrations, while triple combinations appeared more active than the double ones. However, no combination was consistently synergistic against all strains tested. Notably, several studies reported synergy but at concentrations unlikely to be clinically relevant, or the concentration that synergy was observed was unclear. Selecting the most appropriate combinations is likely strain-specific and should be guided by in vitro synergy evaluation. Furthermore, there is an urgent need for clinical studies on the efficacy and safety of such combinations.

show abstract

“…When an MBL enzyme was detected, an in vitro synergism between ceftazidime/avibactam and aztreonam was evaluated using a disk-diffusion approximation test, as published elsewhere, with modifications. 7 Statistical analyses were carried out using SPSS version 13.0 software (IBM, Chicago, IL). Prevalence ratio (PR) and 95% confidence intervals (CIs) were calculated.…”

mentioning

confidence: 99%

Emergence of NDM-producing Pseudomonas aeruginosa among hospitalized patients and impact on antimicrobial therapy during the coronavirus disease 2019 (COVID-19) pandemic

Perez¹,

Carniel

Narváez

2021

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

show abstract

Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring Acinetobacter baumannii and Serratia marcescens Investigated Using Time-Kill and Disk Approximation Assays

Cited by 16 publications

References 16 publications

Carbapenem‐resistant Serratia marcescens bloodstream infection in hematopoietic stem cell transplantation patients: Will it be the next challenge?

Carbapenem‐resistant Serratia marcescens bloodstream infection in hematopoietic stem cell transplantation patients: Will it be the next challenge?

Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant Acinetobacter baumannii

Emergence of NDM-producing Pseudomonas aeruginosa among hospitalized patients and impact on antimicrobial therapy during the coronavirus disease 2019 (COVID-19) pandemic

Contact Info

Product

Resources

About